# Orchard Therapeutics

OTL-200/Libmeldy获EMA批准用于MLD；OTL-203（MPS-I Hurler综合征）注册试验提前1年完成入组；OTL-201（MPS-IIIA）2026年4月获英国创新通行证（ILAP）。

Source: https://cn.bioecon.ru/companies/orchard-therapeutics/
Updated: 2026-06-24

- 国家: United Kingdom

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 监管批准 | Libmeldy/OTL-200已获欧盟委员会、英国MHRA、瑞士Swissmedic及美国FDA批准（在美国以Lenmeldy名称获批） | https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-completes-submission-biologics-license, https://orchard-tx.eu/pipeline/, https://www.orchard-tx.com/approach/pipeline/ |
| 监管批准 | OTL-203已获得EMA PRIME资格及FDA RPD资格 | https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-last-patient-treated, https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-receives-ema-prime-designation-otl-203 |
| 营收 | $19.8M（2023年） | https://www.globaldata.com/company-profile/orchard-therapeutics-plc/ |
| 员工人数 | 163名员工（2023年） | https://www.globaldata.com/company-profile/orchard-therapeutics-plc/ |
| 总部 | 英国伦敦 | https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-receives-ec-approval-libmeldytm-treatment, https://www.globaldata.com/company-profile/orchard-therapeutics-plc/ |

独立来源: globaldata.com, ir.orchard-tx.com, orchard-tx.com, orchard-tx.eu

## 技术

- [个性化与再生医学](https://cn.bioecon.ru/technology/personalized-regenerative-medicine/)